Grifols plasma medicines are a unique class of biologic therapies that require a lengthy and complex manufacturing process, taking up to 12 months from the moment a person donates plasma until when a medicine is ready to be administered to a patient.
We are responsible for every step in the plasma collection and manufacturing process. Grifols has rigorous plasma safety and quality standards, above and beyond the quality and safety standards established by the U.S and international health authorities. These include: careful donor evaluation and screening, highly regulated handling and tracking processes, and state-of-the-art manufacturing processes. We can trace every vial of medicine back to each individual donor and donation.
Grifols researches, develops, produces and markets plasma-derived medicines and other innovative biopharmaceutical solutions to treat patients with chronic, rare and prevalent conditions that can be life-threatening.
Commitment to donors and patients
Patients and donors inspire us every day to achieve our mission of improving people's health and well-being.